

# Pierre Michel Llorca

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1167522/pierre-michel-llorca-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

238  
papers

4,754  
citations

33  
h-index

56  
g-index

300  
ext. papers

6,064  
ext. citations

4.1  
avg, IF

5.41  
L-index

#	Paper	IF	Citations
238	Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.. <i>BMJ, The</i> , <b>2022</b> , 376, e067194	5.9	6
237	Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia.. <i>World Journal of Biological Psychiatry</i> , <b>2022</b> , 1-28	3.8	0
236	Evaluation of a Smartphone Application on the Reduction of Attentional Bias Toward Alcohol Among Students.. <i>Frontiers in Psychology</i> , <b>2022</b> , 13, 790030	3.4	
235	Violent suicide attempt history in elderly patients with bipolar disorder: The role of sex, abdominal obesity, and verbal memory: Results from the FACE-BD cohort (FondaMental Advanced center of Expertise for Bipolar Disorders). <i>Journal of Affective Disorders</i> , <b>2022</b> , 296, 265-276	6.6	0
234	Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 114, 110479	5.5	0
233	Cognitive impairments in treatment-resistant depression: Results from the French cohort of outpatients (FACE-DR). <i>Journal of Affective Disorders Reports</i> , <b>2021</b> , 6, 100272	1.4	
232	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. <i>CNS Drugs</i> , <b>2021</b> , 35, 1189-1205	6.7	3
231	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. <i>Schizophrenia Research</i> , <b>2021</b> , 230, 104-107	3.6	5
230	Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2021</b> , 271, 1571-1578	5.1	2
229	Trajectories of medication adherence in patients with Bipolar Disorder along 2 years-follow-up. <i>Journal of Affective Disorders</i> , <b>2021</b> , 282, 812-819	6.6	3
228	Childhood Trauma increases suicidal behaviour in a treatment-resistant depression population: a FACE-DR report. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 135, 20-27	5.2	3
227	Soutien en emploi : une nouvelle approche vers lâinclusion. <i>Annales Medico-Psychologiques</i> , <b>2021</b> , 179, 370-373	0.2	1
226	Staging, rseaux de symptmes : les nouvelles approches cliniques de la schizophrnie. <i>Annales Medico-Psychologiques</i> , <b>2021</b> , 179, 345-348	0.2	
225	Relationship between childhood physical abuse and clinical severity of treatment-resistant depression in a geriatric population. <i>PLoS ONE</i> , <b>2021</b> , 16, e0250148	3.7	1
224	The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 1674-1684	1.3	3
223	The course of bipolar disorder as a function of the presence and sequence of onset of comorbid alcohol use disorders in outpatients attending the Fondamental Advanced Centres of Expertise. <i>Journal of Affective Disorders</i> , <b>2021</b> , 287, 196-203	6.6	1
222	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 1653-1662	1.3	0

221	Patients' adherence to smartphone apps in the management of bipolar disorder: a systematic review. <i>International Journal of Bipolar Disorders</i> , <b>2021</b> , 9, 19	5.4	4
220	Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. <i>Psychological Medicine</i> , <b>2021</b> , 51, 623-633	6.9	15
219	Association between anhedonia and suicidal events in patients with mood disorders: A 3-year prospective study. <i>Depression and Anxiety</i> , <b>2021</b> , 38, 17-27	8.4	8
218	Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. <i>Acta Psychiatrica Scandinavica</i> , <b>2021</b> , 143, 82-91	6.5	2
217	Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 624-634	1.3	27
216	Characterization of depressed bipolar patients with current suicidal ideation. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2021</b> , 55, 289-304	2.6	4
215	Clinical research in psychopharmacology, the current situation and its perspectives. A conversation with Pierre-Michel Llorca. <i>Therapie</i> , <b>2021</b> , 76, 67-70	3.8	
214	Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 298-308	1.3	11
213	Clinical predictors of recurrences in bipolar disorders type 1 and 2: A FACE-BD longitudinal study. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 134, 129-137	5.2	4
212	Clinical characteristics of bipolar disorders with postpartum depressive onset. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 107, 110225	5.5	3
211	Treatment resistant depression incidence and prevalence using the French nationwide claims database. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 169-177	2.6	5
210	A conceptual framework to develop a patient-reported experience measure of the quality of mental health care: a qualitative study of the PREMIUM project in France. <i>Journal of Market Access &amp; Health Policy</i> , <b>2021</b> , 9, 1885789	3.7	1
209	The Early Impact of the COVID-19 Lockdown on Stress and Addictive Behaviors in an Alcohol-Consuming Student Population in France. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 628631	5	14
208	Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 1208-1217	14.5	42
207	Stigmatization toward People with Anorexia Nervosa, Bulimia Nervosa, and Binge Eating Disorder: A Scoping Review. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	1
206	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 423	8.6	1
205	Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2507-2519	4	
204	Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 110, 110275	5.5	1

203	Psychotropics and COVID-19: An analysis of safety and prophylaxis. <i>L'Encéphale</i> , <b>2021</b> , 47, 564-588	2.9	1
202	Comparison of three scales (BIS, SUMD and BCIS) for measuring insight dimensions and their evolution after one-year of follow-up: Findings from the FACE-SZ Cohort. <i>Psychiatry Research</i> , <b>2021</b> , 303, 114044	9.9	0
201	Childhood maltreatment and metabolic syndrome in bipolar disorders: In search of moderators. <i>Psychoneuroendocrinology</i> , <b>2021</b> , 131, 105327	5	1
200	Pregnancy, delivery and neonatal complications in women with schizophrenia: a national population-based cohort study. <i>Lancet Regional Health - Europe</i> , <b>2021</b> , 10, 100209		4
199	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. <i>Schizophrenia Research</i> , <b>2021</b> , 236, 69-79	3.6	0
198	Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 111, 110335	5.5	2
197	Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study.. <i>Schizophrenia Bulletin Open</i> , <b>2021</b> , 2, sgab012	2.2	3
196	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 4529-4543	15.1	7
195	Patient and physician perspectives of a smartphone application for depression: a qualitative study. <i>BMC Psychiatry</i> , <b>2021</b> , 21, 65	4.2	2
194	Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort. <i>Cognitive Neuropsychiatry</i> , <b>2021</b> , 1-19	2	1
193	Handedness as a neurodevelopmental marker in schizophrenia: Results from the FACE-SZ cohort.. <i>World Journal of Biological Psychiatry</i> , <b>2021</b> , 1-12	3.8	0
192	Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2020</b> , 10, 2045125320926347	4.9	15
191	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study. <i>Psychological Medicine</i> , <b>2020</b> , 1-9	6.9	13
190	Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2020</b> , 101, 109927	5.5	4
189	The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2020</b> , 55, 645-657	4.5	20
188	Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review. <i>L'Encéphale</i> , <b>2020</b> , 46, 193-201	2.9	111
187	Reducing Attentional Bias in Individuals With Alcohol Use Disorders With a Tablet Application: A Randomized Controlled Trial Pilot Study. <i>Alcohol and Alcoholism</i> , <b>2020</b> , 55, 51-55	3.5	2
186	COVID-19 pandemic lockdown and problematic eating behaviors in a student population. <i>Journal of Behavioral Addictions</i> , <b>2020</b> , 9, 826-835	6.3	55

185	Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2020</b> , 10, 2045125320981500	4.9	2
184	Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort. <i>Journal of Affective Disorders</i> , <b>2020</b> , 274, 617-623	6.6	3
183	Adherence to treatment guidelines in clinical practice for using electroconvulsive therapy in major depressive episode. <i>Journal of Affective Disorders</i> , <b>2020</b> , 264, 318-323	6.6	2
182	Recurrent major depressive disorder's impact on end-of-life care of cancer: A nationwide study. <i>Journal of Affective Disorders</i> , <b>2020</b> , 263, 326-335	6.6	4
181	Measuring the Patient Experience of Mental Health Care: A Systematic and Critical Review of Patient-Reported Experience Measures. <i>Patient Preference and Adherence</i> , <b>2020</b> , 14, 2147-2161	2.4	6
180	Evolution and characteristics of the use of valproate in women of childbearing age with bipolar disorder: Results from the FACE-BD cohort. <i>Journal of Affective Disorders</i> , <b>2020</b> , 276, 963-969	6.6	0
179	End-of-Life Care Among Patients With Bipolar Disorder and Cancer: A Nationwide Cohort Study. <i>Psychosomatic Medicine</i> , <b>2020</b> , 82, 722-732	3.7	1
178	Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort. <i>Brain Sciences</i> , <b>2020</b> , 10,	3.4	6
177	Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study. <i>Journal of Affective Disorders</i> , <b>2019</b> , 259, 210-217	6.6	9
176	Impact of Positive Emotion Regulation Training on Negative Symptoms and Social Functioning in Schizophrenia: A Field Test. <i>Frontiers in Psychiatry</i> , <b>2019</b> , 10, 532	5	11
175	Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission. <i>Psychiatry Research</i> , <b>2019</b> , 281, 112560	9.9	8
174	Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental). <i>BMC Psychiatry</i> , <b>2019</b> , 19, 50	4.2	13
173	Pharmacotherapy for the peripartum management of bipolar disorder. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1731-1741	4	4
172	Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 94, 109654	5.5	5
171	Effects of depression and cognitive impairment on quality of life in older adults with schizophrenia spectrum disorder: Results from a multicenter study. <i>Journal of Affective Disorders</i> , <b>2019</b> , 256, 164-175	6.6	10
170	Relationship between childhood trauma and level of insight in schizophrenia: A path-analysis in the national FACE-SZ dataset. <i>Schizophrenia Research</i> , <b>2019</b> , 208, 90-96	3.6	4
169	The Patient-Reported Experience Measure for Improving qQuality of care in Mental health (PREMIUM) project in France: study protocol for the development and implementation strategy. <i>Patient Preference and Adherence</i> , <b>2019</b> , 13, 165-177	2.4	10
168	A multi-dimensional approach to the relationship between insight and aggressiveness in schizophrenia: Findings from the FACE-SZ cohort. <i>Schizophrenia Research</i> , <b>2019</b> , 204, 38-45	3.6	3

167	Pharmacotherapeutic approaches to treating depression during the perimenopause. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1837-1845	4	3
166	End-of-life care among patients with schizophrenia and cancer: a population-based cohort study from the French national hospital database. <i>Lancet Public Health</i> , <b>2019</b> , 4, e583-e591	22.4	30
165	Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1674115	3.7	
164	Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	14
163	Results and validation of an index to measure health state of patients with depression in automated healthcare databases. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1562860	3.7	1
162	Prevalence of maternal psychological disorders after immediate postpartum haemorrhage: a repeated cross-sectional study - the PSYCHE* study protocol. <i>BMJ Open</i> , <b>2019</b> , 9, e027390	3	2
161	Machine learning for predicting psychotic relapse at 2 years in schizophrenia in the national FACE-SZ cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 92, 8-18	5.5	19
160	Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort. <i>Journal of Affective Disorders</i> , <b>2019</b> , 245, 468-474	6.6	6
159	Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 92, 226-234	5.5	8
158	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , <b>2019</b> , 49, 1378-1391	6.9	42
157	Health-related quality of life in alcohol dependence: Similar cross-cultural impact beyond specific drinking habits. <i>Journal of Ethnicity in Substance Abuse</i> , <b>2019</b> , 18, 279-295	1.1	2
156	Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2018</b> , 85, 62-68	5.5	9
155	Serotonin transporter gene expression predicts the worsening of suicidal ideation and suicide attempts along a long-term follow-up of a Major Depressive Episode. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 401-414	1.2	12
154	Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 24-36	1.2	12
153	Shared Decision-Making: a Systematic Review Focusing on Mood Disorders. <i>Current Psychiatry Reports</i> , <b>2018</b> , 20, 23	9.1	23
152	Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2018</b> , 268, 749-755	5.1	19
151	Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS <sup>®</sup> ): A six-month post-discharge prospective study. <i>Schizophrenia Research</i> , <b>2018</b> , 193, 114-118	3.6	13
150	Validation of a four items version of the Functional Remission of General Schizophrenia scale (the mini-FROGS) to capture the functional benefits of clinical remission. <i>European Psychiatry</i> , <b>2018</b> , 47, 35-41	6	7



149	Influence of Venus and Mars in the cognitive sky of schizophrenia. Results from the first-step national FACE-SZ cohort. <i>Schizophrenia Research</i> , <b>2018</b> , 195, 357-365	3.6	6
148	Risk factors for increased duration of untreated psychosis. Results from the FACE-SZ dataset. <i>Schizophrenia Research</i> , <b>2018</b> , 195, 529-533	3.6	12
147	The in Vitro Actions of Loxapine on Dopaminergic and Serotonergic Receptors. Time to Consider Atypical Classification of This Antipsychotic Drug?. <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 355-360	5.8	5
146	Anatomical predictors of cognitive decline after subthalamic stimulation in Parkinson's disease. <i>Brain Structure and Function</i> , <b>2018</b> , 223, 3063-3072	4	7
145	Baseline results from the European non-interventional Antipsychotic Long acting injection in schizophrenia (ALTO) study. <i>European Psychiatry</i> , <b>2018</b> , 52, 85-94	6	10
144	Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. <i>British Journal of Psychiatry</i> , <b>2018</b> , 213, 464-470	5.4	25
143	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 36-46	14.5	154
142	Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1878-1886	7	22
141	Health related quality of life in patients having schizophrenia negative symptoms - a systematic review. <i>Journal of Market Access &amp; Health Policy</i> , <b>2018</b> , 6, 1517573	3.7	4
140	Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort. <i>Psychiatry Research</i> , <b>2018</b> , 270, 104-110	9.9	11
139	Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort. <i>Schizophrenia Research</i> , <b>2018</b> , 201, 373-380	3.6	17
138	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , <b>2017</b> , 17, 593-609	4.3	46
137	Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort. <i>Schizophrenia Research</i> , <b>2017</b> , 185, 173-181	3.6	35
136	Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2017</b> , 210, 280-286	6.6	40
135	Advanced paternal age is associated with earlier schizophrenia onset in offspring. Results from the national multicentric FACE-SZ cohort. <i>Psychiatry Research</i> , <b>2017</b> , 254, 218-223	9.9	5
134	Troubles moteurs tardifs induits par antipsychotiques : mise au point. <i>Annales Medico-Psychologiques</i> , <b>2017</b> , 175, 474-479	0.2	
133	Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2017</b> , 267, 567-577	5.1	16
132	Would I take antipsychotics, if I had psychotic symptoms? Examining determinants of the decision to take antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2017</b> , 77, 155-163	5.5	7

131	Comparison between the WHO and NIAAA criteria for binge drinking on drinking features and alcohol-related aftermaths: Results from a cross-sectional study among eight emergency wards in France. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 175, 92-98	4.9	10
130	A Multilevel Functional Study of a At-Risk Variant for Bipolar Disorder and Schizophrenia. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 10389-10397	6.6	25
129	Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation. <i>L'Encephale</i> , <b>2017</b> , 43, 303-310	2.9	2
128	Alcohol use and bipolar disorder comorbidity: Synthesis and perspectives. <i>European Psychiatry</i> , <b>2017</b> , 41, S470-S470	6	
127	Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. <i>Psychiatry Research</i> , <b>2017</b> , 257, 315-321	9.9	30
126	A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1372026	3.7	1
125	Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 94, 62-69	5.2	10
124	Determinants of Functioning in Euthymic Patients with Bipolar Disorder: A Structural Equation Modelling Approach. <i>European Psychiatry</i> , <b>2017</b> , 41, S77-S77	6	
123	Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2017</b> , 79, 332-339	5.5	26
122	Management of treatment resistant depression: A comparison between French expert consensus guidelines and international evidence based guidelines. <i>European Psychiatry</i> , <b>2017</b> , 41, S525-S525	6	
121	Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. <i>Schizophrenia Research</i> , <b>2017</b> , 182, 84-89	3.6	24
120	Creating an index to measure health state of depressed patients in automated healthcare databases: the methodology. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1372025	3.7	3
119	What's New in Addiction Prevention in Young People: A Literature Review of the Last Years of Research. <i>Frontiers in Psychology</i> , <b>2017</b> , 8, 1131	3.4	55
118	Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental). <i>Frontiers in Psychiatry</i> , <b>2017</b> , 8, 244	5	8
117	Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: Factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173267	3.7	6
116	Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia. <i>Schizophrenia Research</i> , <b>2016</b> , 178, 1-5	3.6	8
115	Psychopharmacology during residents's training: The role of scientific societies. <i>European Psychiatry</i> , <b>2016</b> , 33, S62-S62	6	
114	Influence of lithium on sleep and chronotypes in remitted patients with bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2016</b> , 204, 32-9	6.6	14



113	A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. <i>Schizophrenia Research</i> , <b>2016</b> , 171, 27-34	3.6	52
112	Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 403-11	4.1	3
111	Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. <i>Journal of Affective Disorders</i> , <b>2016</b> , 191, 209-15	6.6	26
110	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 921-36	4	22
109	Assessment and management of agitation in psychiatry: Expert consensus. <i>World Journal of Biological Psychiatry</i> , <b>2016</b> , 17, 86-128	3.8	146
108	Telephone-administered psychotherapy in combination with antidepressant medication for the acute treatment of major depressive disorder. <i>Journal of Affective Disorders</i> , <b>2016</b> , 190, 6-11	6.6	11
107	Potential serotonergic agents for the treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 159-70	5.9	29
106	Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence: Results From the FACE-SZ Dataset. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, e1130-e1136	4.6	22
105	Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	10
104	Executive Functions in Tobacco Dependence: Importance of Inhibitory Capacities. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150940	3.7	14
103	Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. <i>Bipolar Disorders</i> , <b>2016</b> , 18, 164-73	3.8	58
102	Investigational drugs for treating agitation in persons with dementia. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 973-83	5.9	21
101	The EVACO Project: A new battery for assessing social cognition disorders and related psychiatric disability in schizophrenia. <i>European Psychiatry</i> , <b>2016</b> , 33, S78-S78	6	2
100	Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. <i>Schizophrenia Research</i> , <b>2016</b> , 175, 161-167	3.6	16
99	Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 1290-302	1.3	64
98	Intérêt de l'éducation thérapeutique chez les malades souffrant de schizophrénie : le programme SCHIZÉDUC. <i>Annales Medico-Psychologiques</i> , <b>2015</b> , 173, 97-100	0.2	0
97	Behavioral and electrophysiological investigation of semantic and response conflict in the Stroop task. <i>Psychonomic Bulletin and Review</i> , <b>2015</b> , 22, 543-9	4.1	20
96	An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness. <i>Journal of Affective Disorders</i> , <b>2015</b> , 185, 97-103	6.6	7

95	Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 910-22	4.6	26
94	A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap. <i>European Psychiatry</i> , <b>2015</b> , 30, 728-35	6	61
93	Google Trends: Ready for real-time suicide prevention or just a Zeta-Jones effect? An exploratory study. <i>Psychiatry Research</i> , <b>2015</b> , 228, 913-7	9.9	27
92	A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia. <i>Translational Psychiatry</i> , <b>2015</b> , 5, e608	8.6	18
91	The World Health Organization (WHO) dataset for guiding suicide prevention policies: A 3-decade French national survey. <i>Journal of Affective Disorders</i> , <b>2015</b> , 188, 232-8	6.6	3
90	Risk factors for treatment resistance in unipolar depression: a systematic review. <i>Journal of Affective Disorders</i> , <b>2015</b> , 171, 137-41	6.6	74
89	Addendum: Brousse, G.; et al. Alcohol risk reduction in France: a modernised approach related to alcohol misuse disorders. <i>Int. J. Environ. Res. Public Health</i> 2014, 11, 11664-11675. <i>International Journal of Environmental Research and Public Health</i> , <b>2015</b> , 12, 5406-7	4.6	
88	The ability of early changes in motivation to predict later antidepressant treatment response. <i>Neuropsychiatric Disease and Treatment</i> , <b>2015</b> , 11, 2875-82	3.1	10
87	Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort. <i>Schizophrenia Research</i> , <b>2015</b> , 168, 388-94	3.6	42
86	Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. <i>Schizophrenia Research</i> , <b>2015</b> , 169, 255-261	3.6	27
85	Interest of clozapine and paliperidone palmitate plasma concentrations to monitor treatment in schizophrenic patients on chronic hemodialysis. <i>Schizophrenia Research</i> , <b>2015</b> , 166, 351-2	3.6	2
84	Validation of a Psycho-Sensory hallucinations Scale (PSAS) in schizophrenia and Parkinson's disease. <i>Schizophrenia Research</i> , <b>2015</b> , 161, 269-76	3.6	19
83	Preventing Alcohol Abuse Through Social Networking Sites: A First Assessment of a Two-Year Ecological Approach. <i>Journal of Medical Internet Research</i> , <b>2015</b> , 17, e278	7.6	11
82	Morningness-eveningness and treatment response in major depressive disorder. <i>Chronobiology International</i> , <b>2014</b> , 31, 283-9	3.6	28
81	Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 1792-1800	8.8	9
80	Avis critique sur la place du lithium dans les recommandations professionnelles sur la prise en charge du trouble bipolaire. <i>Annales Medico-Psychologiques</i> , <b>2014</b> , 172, 177-181	0.2	
79	Alcoholism risk reduction in France: a modernised approach related to alcohol misuse disorders. <i>International Journal of Environmental Research and Public Health</i> , <b>2014</b> , 11, 11664-75	4.6	4
78	Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 729-36	1.3	186

77	Quetiapine extended release for the treatment of bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , <b>2014</b> , 14, 987-1005	4.3	5
76	How CAGE, RAPS4-QF, and AUDIT Can Help Practitioners for Patients Admitted with Acute Alcohol Intoxication in Emergency Departments?. <i>Frontiers in Psychiatry</i> , <b>2014</b> , 5, 72	5	2
75	Patients' perspectives on residual symptoms in bipolar disorder: a focus group study. <i>Journal of Nervous and Mental Disease</i> , <b>2014</b> , 202, 550-5	1.8	15
74	Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 426-34	1.7	25
73	Residual symptoms and functional performance in a large sample of euthymic bipolar patients in France (the OPTHYMUM study). <i>Journal of Affective Disorders</i> , <b>2014</b> , 159, 94-102	6.6	25
72	A composite scale applied to evaluate anxiety in schizophrenic patients (SAES). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2014</b> , 264, 171-8	5.1	10
71	Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?. <i>Comprehensive Psychiatry</i> , <b>2013</b> , 54, 309-20	7.3	14
70	Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale. <i>Comprehensive Psychiatry</i> , <b>2013</b> , 54, 1016-22	7.3	15
69	Bilateral lesions of the nigrostriatal pathways are associated with chronic mechanical pain hypersensitivity in rats. <i>Neuroscience Research</i> , <b>2013</b> , 76, 261-4	2.9	21
68	Screening hypersexuality in Parkinson's disease in everyday practice. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 242-6	3.6	19
67	Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. <i>European Psychiatry</i> , <b>2013</b> , 28, 362-71	6	24
66	Asenapine in bipolar I disorder: evidence and place in patient management. <i>Therapeutic Advances in Chronic Disease</i> , <b>2013</b> , 4, 5-14	4.9	11
65	Clinicians' attitudes toward the use of long-acting injectable antipsychotics. <i>Journal of Nervous and Mental Disease</i> , <b>2013</b> , 201, 553-9	1.8	24
64	Treatment in hospital for alcohol-dependent patients decreases attentional bias. <i>Neuropsychiatric Disease and Treatment</i> , <b>2013</b> , 9, 773-9	3.1	11
63	Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. <i>European Psychiatry</i> , <b>2012</b> , 27, 396-400	6	22
62	Time-stability of the "Functional Remission of General Schizophrenia" (FROGS) scale. <i>European Psychiatry</i> , <b>2012</b> , 27, 437-41	6	11
61	The influence of therapeutic alliance and insight on medication adherence in schizophrenia. <i>Nordic Journal of Psychiatry</i> , <b>2012</b> , 66, 49-54	2.3	46
60	CAGE, RAPS4, RAPS4-QF and AUDIT screening tests for men and women admitted for acute alcohol intoxication to an emergency department: are standard thresholds appropriate?. <i>Alcohol and Alcoholism</i> , <b>2012</b> , 47, 273-81	3.5	16

59	Alteration of glutamate/GABA balance during acute alcohol withdrawal in emergency department: a prospective analysis. <i>Alcohol and Alcoholism</i> , <b>2012</b> , 47, 501-8	3.5	23
58	Current status and management of patients with bipolar disorder in France in 2011. <i>International Clinical Psychopharmacology</i> , <b>2012</b> , 28, e50	2.2	
57	The Functional Recovery Scale in Schizophrenia (FRSS): Relationship to panss. <i>European Psychiatry</i> , <b>2011</b> , 26, 2073-2073	6	
56	A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. <i>Schizophrenia Research</i> , <b>2011</b> , 125, 284-90	3.6	64
55	Body weight gain and deep brain stimulation. <i>Journal of the Neurological Sciences</i> , <b>2011</b> , 310, 267-70	3.2	40
54	Clinical potential of lurasidone in the management of schizophrenia. <i>Therapeutics and Clinical Risk Management</i> , <b>2011</b> , 7, 239-50	2.9	26
53	Measuring preventive procedures by French GPs: an observational survey. <i>British Journal of General Practice</i> , <b>2011</b> , 61, e31-41	1.6	4
52	Adherence to guidelines by French psychiatrists in their real world of clinical practice. <i>Journal of Nervous and Mental Disease</i> , <b>2011</b> , 199, 239-43	1.8	27
51	Hypersexuality and pathological gambling in Parkinson's disease: A cross-sectional case-control study. <i>Movement Disorders</i> , <b>2011</b> , 26, 2127-30	7	19
50	Diagnostic criteria for apathy in clinical practice. <i>International Journal of Geriatric Psychiatry</i> , <b>2011</b> , 26, 158-65	3.9	139
49	Genetic and molecular exploration of UHMK1 in schizophrenic patients. <i>Psychiatric Genetics</i> , <b>2011</b> , 21, 315-8	2.9	6
48	Discussion of prevalence and management of discomfort when swallowing pills: orodispersible tablets expand treatment options in patients with depression. <i>Therapeutic Delivery</i> , <b>2011</b> , 2, 611-22	3.8	15
47	Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. <i>Patient Preference and Adherence</i> , <b>2010</b> , 4, 325-34	2.4	4
46	Could the inter-individual variability in cocaine-induced psychotic effects influence the development of cocaine addiction? Towards a new pharmacogenetic approach to addictions. <i>Medical Hypotheses</i> , <b>2010</b> , 75, 600-4	3.8	19
45	Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. <i>Psychiatry Research</i> , <b>2010</b> , 179, 12-8	9.9	14
44	Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research. <i>Fundamental and Clinical Pharmacology</i> , <b>2010</b> , 24, 139-60	3.1	15
43	Validity study of Kessler's psychological distress scales conducted among patients admitted to French emergency department for alcohol consumption-related disorders. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2010</b> , 34, 1235-45	3.7	46
42	Outcomes from primary care management of alcohol dependence in France. <i>Journal of Substance Abuse Treatment</i> , <b>2009</b> , 36, 457-62	4.2	9

41	Hypothermie aux antipsychotiques : particularités chez le sujet âgé souffrant de schizophrénie. <i>Annales Medico-Psychologiques</i> , <b>2009</b> , 167, 397-403	0.2	
40	The "Functional Remission of General Schizophrenia" (FROGS) scale: development and validation of a new questionnaire. <i>Schizophrenia Research</i> , <b>2009</b> , 113, 218-25	3.6	73
39	Benzodiazepine dependence: focus on withdrawal syndrome. <i>Annales Pharmaceutiques Françaises</i> , <b>2009</b> , 67, 408-13	1.3	31
38	Intérêt du programme de psychoéducation insight dans le traitement d'une dépression chez un patient souffrant de schizophrénie : étude de cas. <i>Journal De Thérapie Comportementale Et Cognitive</i> , <b>2009</b> , 19, 102-106	0.2	4
37	Validation de l'échelle d'évaluation du risque suicidaire RSD après tentative de suicide chez 320 patients hospitalisés dans un service d'urgence. <i>Journal De Thérapie Comportementale Et Cognitive</i> , <b>2009</b> , 19, 47-52	0.2	1
36	A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study design. <i>Journal of Clinical Psychopharmacology</i> , <b>2009</b> , 29, 96-7	1.7	
35	Is pregnancy the time to change alcohol consumption habits in France?. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2008</b> , 32, 868-73	3.7	26
34	Partial compliance in schizophrenia and the impact on patient outcomes. <i>Psychiatry Research</i> , <b>2008</b> , 161, 235-47	9.9	123
33	Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. <i>L'Encephale</i> , <b>2008</b> , 34, 170-8	2.9	14
32	Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. <i>European Neuropsychopharmacology</i> , <b>2008</b> , 18, 673-81	1.2	53
31	Indications des NAP : précoces ou tardives ?. <i>L'Encephale</i> , <b>2008</b> , 34, S232-S236	2.9	0
30	Développement d'un programme psycho-éducatif ciblé sur l'insight pour les patients souffrant de schizophrénie. <i>Information Psychiatrique</i> , <b>2008</b> , 84, 937		1
29	Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 46, 14-22	2	30
28	Tardive dyskinesia and glucid metabolism. <i>Human Psychopharmacology</i> , <b>2007</b> , 22, 373-80	2.3	0
27	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. <i>European Journal of Pharmaceutical Sciences</i> , <b>2007</b> , 32, 357-66	5.1	8
26	Occult maternal exposure to environmental tobacco smoke exposure. <i>Tobacco Control</i> , <b>2007</b> , 16, 64-5	5.3	13
25	Les modalités de consommation : de l'usage à la dépendance. <i>Annales Medico-Psychologiques</i> , <b>2007</b> , 165, 439-442	0.2	
24	Intérêt des prises en charge coordonnées : l'alcoologie de liaison et les réseaux de santé. <i>Annales Medico-Psychologiques</i> , <b>2007</b> , 165, 449-453	0.2	

23	Du dñi de grossesse au nðnaticide : hypothèses diagnostiques autour d'ũn cas. <i>Annales Medico-Psychologiques</i> , <b>2007</b> , 165, 671-675	0.2	1
22	Activit' anxioleptique de la cyamfazine : rñle des rñcepteurs s'fotoninergiques. <i>Information Psychiatrique</i> , <b>2007</b> , 83, 595		0
21	Recurrent herpes and post-traumatic stress disorder. <i>Herpes: the Journal of the IHMF</i> , <b>2007</b> , 14, 72-4		
20	ALQoL 9 for measuring quality of life in alcohol dependence. <i>Alcohol and Alcoholism</i> , <b>2006</b> , 41, 181-7	3.5	35
19	Symptom control, functioning, and hospitalization status in French patients changed from oral atypical antipsychotics to risperidone long-acting injectable. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2006</b> , 10, 276-84	2.4	3
18	Insight et observance dans la schizophrñie. <i>Annales Medico-Psychologiques</i> , <b>2006</b> , 164, 154-158	0.2	4
17	Comorbidit's somatiques chez les patients souffrant de schizophrñie trait'e. Recommandations actuelles. <i>Annales Medico-Psychologiques</i> , <b>2006</b> , 164, 159-164	0.2	5
16	Alcohol consumption during pregnancy: a urge to increase prevention and screening. <i>European Journal of Epidemiology</i> , <b>2006</b> , 21, 787-8	12.1	16
15	Validity of the CAGE questionnaire in hospital. <i>European Psychiatry</i> , <b>2005</b> , 20, 484-9	6	31
14	Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. <i>International Clinical Psychopharmacology</i> , <b>2005</b> , 20, 121-30	2.2	92
13	Performance of asialotransferrin in detecting alcohol abuse. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2005</b> , 29, 81-3	3.7	12
12	Efficacy of escitalopram in patients with severe depression: a pooled analysis. <i>International Journal of Clinical Practice</i> , <b>2005</b> , 59, 268-75	2.9	56
11	Multicenter validation study of the %CDT TIA kit in alcohol abuse and alcohol dependence. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2004</b> , 28, 1331-7	3.7	15
10	The use of biological laboratory markers in the diagnosis of alcohol misuse: an evidence-based approach. <i>Drug and Alcohol Dependence</i> , <b>2004</b> , 74, 273-9	4.9	31
9	Comparison of escitalopram and citalopram efficacy: A meta-analysis. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2003</b> , 7, 259-68	2.4	50
8	Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64, 1250-7	4.6	236
7	General practitioners and alcohol use disorders: quantity without quality. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2003</b> , 27, 61-6	3.7	2
6	SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. <i>Psychiatry Research - Neuroimaging</i> , <b>2002</b> , 115, 37-48	2.9	31



5	Dépansions sées, difficiles et résistantes : aspects cliniques et thérapeutiques. <i>Annales Medico-Psychologiques</i> , <b>2002</b> , 160, 475-482	0.2	
4	Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2002</b> , 26, 481-5	5.5	33
3	Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. <i>Journal of Psychiatry and Neuroscience</i> , <b>2002</b> , 27, 30-7	4.5	31
2	Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 1020-7	4.6	79
1	The use of benzodiazepines in schizophrenia: a review. <i>European Psychiatry</i> , <b>1991</b> , 6, 217-222	6	5